Allogene Therapeutics, Inc. Gains 39.22%
Allogene Therapeutics, Inc. (ALLO:NASDAQ) shot up at $2.84, a gain of 39.2%. On Tue, Feb 18, 2025, ALLO:NASDAQ touched a New 2-Week High of $2.84. The stock appeared on our News Catalysts scanner on Fri, Feb 14, 2025 at 11:41 AM in the 'AGREEMENT' category. From Tue, Feb 04, 2025, the stock recorded 44.44% Up Days and 40.00% Green Days
The stock spiked on Tue, Feb 18, 2025 at $3.76 with a volume of 75M+.
About Allogene Therapeutics, Inc. (ALLO:NASDAQ)
Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Top 10 Gainers:
- GCL Global Holdings Ltd (GCL:NASDAQ), 153.38%
- Energy Focus, Inc. (EFOI:NASDAQ), 109.23%
- F45 Training Holdings Inc. (FXLV:NYSE), 92.08%
- KWESST Micro Systems Inc. (KWE:NASDAQ), 70.06%
- Aditxt Inc. (ADTX:NASDAQ), 57.14%
- GeneDx Holdings Corp Cl A (WGS:NASDAQ), 47.69%
- Nikola Corporation (NKLA:NASDAQ), 41.44%
- Allogene Therapeutics, Inc. (ALLO:NASDAQ), 39.22%
- Digital Ally, Inc. (DGLY:NASDAQ), 36.64%
- Top Wealth Group Holding Limited (TWG:NASDAQ), 35.86%